MedPath

Is oral tablet misoprostol more effective and safer than injectible drug oxytocin in pregnant women at term whose membranes ruptured before the onset of labour pains.

Phase 3
Recruiting
Conditions
Pregnant women at term with prelabour rupture of membranes
Registration Number
CTRI/2016/02/006637
Lead Sponsor
Dept of Obstetrics and Gynaecology Christian Medical College and Hospital
Brief Summary

This is a prospective  randomized controlled unmasked trial which will be done in pregnant women at term  with pre-labour rupture of membranes. Active or planned management in pre-labour rupture of membranes redues maternal infectious morbidity and   neonatal care unit admission  when compared to  expectant management [1]. There are different methods of induction of labour for pre-labour rupture of membranes. In this study we are comparing oral misoprostol to intravenous oxytocin for induction of labour.  Research done in this institution [2] on term inductions without rupture of membranes has shown that women in the group that received oral misoprostol were more likely to develop uterine contractions without oxytocin than women given vaginal  misoprostol. Thus due to ease of administration especially in women with rupture of membranes ,we deciced to use oral misopostol. Women in the arm randomized to oxytocin will be induced with usual oxytocin protocol followed in labour room for induction of labour. Women randomized to oral misoprostol will be given oral misoprostol 50mcg at four hourly inteval maximum of three doses in primi gravida and two doses in multi gravida.These women then be induced with oxytocin after twelve hours of first dose of oral misoprostol if they do not have uterine contractions.After informed consent, women will be recruited from labour room and randomized to either of the groups. Data regarding duration of labour, fever ,CTG abnormalities, neonatal morbidity etc, will be collected. The data collected will be  analysed to compare safety  and efficacy in both groups.  BIBLIOGRAPHY:

1.Dare MR, Middleton P, Crowther CA, Flendy FJ, Varatharaju B. Planned early birth vresus expectant management (waiting) for prelabour rupture of membranes at term (37 weeks or more).Cochrane Database Syst rev  2006 jan 25;(1):CD005302.

2. A radomized double mask placebo controlled  trial comparing oral misoprostol with vaginal misoprostol for induction of labour. Dr.HIlda Yenuberi, Dr.Anuja Abraham, Dr.Ajit Sabastian, Dr.SAnthosh Joseph Benjamin,Dr.Visalakshi Jayasheelan, Dr.Jiji Elizebeth Mathew Awaiting Publication.

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Female
Target Recruitment
200
Inclusion Criteria

•Pregnancies between 37 – 41 weeks of gestation with singleton foetus with vertex presentation •Reassuring fetal heart rate •Definite diagnosis of PROM.

Exclusion Criteria
  • Contraindications to vaginal delivery -Previous uterine scar -Diagnosis of labour -Meconium stained liquor -Clinical estimated fetal weight > 4 kgs -Evidence of chorioamnionitis, temperature > 100.4 degree Fahrenheit, uterine tenderness or foul smelling amniotic fluid.
  • Any severe medical disease like diabetes on insulin or severe pre-eclampsia.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
-Duration between induction and deliveryDifference of 2 hours from induction to delivery. 5% difference in LSCS rates
-Vaginal delivery achieved within 24 hoursDifference of 2 hours from induction to delivery. 5% difference in LSCS rates
-Caesarean sectionDifference of 2 hours from induction to delivery. 5% difference in LSCS rates
Secondary Outcome Measures
NameTimeMethod
-Need for oxytocin augmentation -Serious neonatal morbidity or perinatal death eg sepsis,seizures,birth asphyxia,neonatal encephalopathy-Serious maternal morbidity or death eg sepsis,admission to ICU,septicaemia,traumatic PPH-Fever, chorioamnionitis, endometritis-Apgar score less than seven at five minutes-Neonatal intensive care unit admission-Maternal nausea-Maternal diarrhea-Other maternal side-effects-PPH more than500ml of blood loss -Woman and Caregiver not satisfiedSoon after delivery.

Trial Locations

Locations (1)

Department of obstetrics and gynaecology

🇮🇳

Vellore, TAMIL NADU, India

Department of obstetrics and gynaecology
🇮🇳Vellore, TAMIL NADU, India
Dr Shiny Nirupama Boddu
Principal investigator
7094910812
nirupamashiny@yahoo.co.in

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.